In the past week, HALO stock has gone up by 1.42%, with a monthly gain of 17.22% and a quarterly surge of 11.81%. The volatility ratio for the week is 2.63%, and the volatility levels for the last 30 days are 2.87% for Halozyme Therapeutics Inc The simple moving average for the last 20 days is 5.34% for HALO stock, with a simple moving average of 9.16% for the last 200 days.
Is It Worth Investing in Halozyme Therapeutics Inc (NASDAQ: HALO) Right Now?
The price-to-earnings ratio for Halozyme Therapeutics Inc (NASDAQ: HALO) is 18.67x, which is above its average ratio. Moreover, the 36-month beta value for HALO is 1.25. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for HALO is 125.89M and currently, short sellers hold a 7.47% of that float. On January 31, 2025, HALO’s average trading volume was 1.70M shares.
HALO) stock’s latest price update
Halozyme Therapeutics Inc (NASDAQ: HALO) has seen a rise in its stock price by 1.06 in relation to its previous close of 55.83. However, the company has experienced a 1.42% gain in its stock price over the last five trading sessions. zacks.com reported 2025-01-28 that Whether you’re a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Analysts’ Opinion of HALO
Many brokerage firms have already submitted their reports for HALO stocks, with Wells Fargo repeating the rating for HALO by listing it as a “Equal Weight.” The predicted price for HALO in the upcoming period, according to Wells Fargo is $62 based on the research report published on October 07, 2024 of the previous year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see HALO reach a price target of $57, previously predicting the price at $52. The rating they have provided for HALO stocks is “Neutral” according to the report published on September 19th, 2024.
Piper Sandler gave a rating of “Neutral” to HALO, setting the target price at $51 in the report published on June 07th of the previous year.
HALO Trading at 12.97% from the 50-Day Moving Average
After a stumble in the market that brought HALO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.91% of loss for the given period.
Volatility was left at 2.87%, however, over the last 30 days, the volatility rate increased by 2.63%, as shares surge +17.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.56% upper at present.
During the last 5 trading sessions, HALO rose by +1.42%, which changed the moving average for the period of 200-days by +46.13% in comparison to the 20-day moving average, which settled at $53.56. In addition, Halozyme Therapeutics Inc saw 18.01% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HALO starting from Henderson Jeffrey William, who sale 10,000 shares at the price of $50.01 back on Jan 06 ’25. After this action, Henderson Jeffrey William now owns 43,611 shares of Halozyme Therapeutics Inc, valued at $500,060 using the latest closing price.
JEFFREY HENDERSON, the Director of Halozyme Therapeutics Inc, proposed sale 10,000 shares at $47.74 during a trade that took place back on Jan 06 ’25, which means that JEFFREY HENDERSON is holding shares at $477,400 based on the most recent closing price.
Stock Fundamentals for HALO
Current profitability levels for the company are sitting at:
- 0.5 for the present operating margin
- 0.78 for the gross margin
The net margin for Halozyme Therapeutics Inc stands at 0.41. The total capital return value is set at 0.24. Equity return is now at value 111.83, with 19.57 for asset returns.
Based on Halozyme Therapeutics Inc (HALO), the company’s capital structure generated 0.77 points at debt to capital in total, while cash flow to debt ratio is standing at 0.27. The debt to equity ratio resting at 3.32. The interest coverage ratio of the stock is 25.41.
Currently, EBITDA for the company is 451.95 million with net debt to EBITDA at 2.37. When we switch over and look at the enterprise to sales, we see a ratio of 9.0. The receivables turnover for the company is 3.32for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.36.
Conclusion
To wrap up, the performance of Halozyme Therapeutics Inc (HALO) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
